Treasury Secretary Jacob Lew said in Senate testimony this week that it may be possible to re-examine the 2.3% medical device tax, but that revenue from the tax would have to be replaced if the tax was repealed. AdvaMed CEO Stephen Ubl responded to Lew's testimony by saying that overturning the tax isn't a question of health policy but is key to economic growth and tax reform. "Repealing it will have no effect on the programs authorized under the Affordable Care Act," he said.

Related Summaries